Immatics Begin Period Cash Flow from 2010 to 2024

IMTXW Stock  USD 0.40  0.06  13.04%   
Immatics Biotechnologies Begin Period Cash Flow yearly trend continues to be fairly stable with very little volatility. Begin Period Cash Flow will likely drop to about 117.4 M in 2024. Begin Period Cash Flow is the amount of cash immatics biotechnologies GmbH has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities. View All Fundamentals
 
Begin Period Cash Flow  
First Reported
2018-03-31
Previous Quarter
122.2 M
Current Value
158.1 M
Quarterly Volatility
82.2 M
 
Covid
Check Immatics Biotechnologies financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Immatics Biotechnologies' main balance sheet or income statement drivers, such as Tax Provision of 0.0, Net Interest Income of 13.7 M or Interest Income of 14.5 M, as well as many indicators such as Price To Sales Ratio of 13.5, Dividend Yield of 0.0 or PTB Ratio of 3.58. Immatics financial statements analysis is a perfect complement when working with Immatics Biotechnologies Valuation or Volatility modules.
  
Check out the analysis of Immatics Biotechnologies Correlation against competitors.

Latest Immatics Biotechnologies' Begin Period Cash Flow Growth Pattern

Below is the plot of the Begin Period Cash Flow of immatics biotechnologies GmbH over the last few years. It is the amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities. Immatics Biotechnologies' Begin Period Cash Flow historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Immatics Biotechnologies' overall financial position and show how it may be relating to other accounts over time.
Begin Period Cash Flow10 Years Trend
Slightly volatile
   Begin Period Cash Flow   
       Timeline  

Immatics Begin Period Cash Flow Regression Statistics

Arithmetic Mean54,990,931
Geometric Mean23,685,286
Coefficient Of Variation123.05
Mean Deviation57,974,308
Median8,415,000
Standard Deviation67,663,898
Sample Variance4578.4T
Range199.1M
R-Value0.80
Mean Square Error1811.8T
R-Squared0.63
Significance0.0004
Slope12,033,406
Total Sum of Squares64097.6T

Immatics Begin Period Cash Flow History

2024117.4 M
2023148.5 M
2022133 M
2021207.5 M
2020103.4 M
201939.4 M

About Immatics Biotechnologies Financial Statements

Immatics Biotechnologies investors use historical fundamental indicators, such as Immatics Biotechnologies' Begin Period Cash Flow, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Immatics Biotechnologies. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Begin Period Cash Flow148.5 M117.4 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Immatics Stock Analysis

When running Immatics Biotechnologies' price analysis, check to measure Immatics Biotechnologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immatics Biotechnologies is operating at the current time. Most of Immatics Biotechnologies' value examination focuses on studying past and present price action to predict the probability of Immatics Biotechnologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immatics Biotechnologies' price. Additionally, you may evaluate how the addition of Immatics Biotechnologies to your portfolios can decrease your overall portfolio volatility.